Health Canada recently issued the first certificates of supplementary protection (CSPs) against the following approvals:
- neisseria meningitidis grp B recombinant lipoprotein 2086 sub-family A/neisseria meningitidis group B recombinant lipoprotein 2086 sub-family B (Pfizer's Trumenba);
- letermovir (Merck's Prevymis); and
- guselkumab (Tremfya).(1)
In addition, on April 1 2018 the CSP application fee was increased to C$9,192.
For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.